All In Biotech

Drug Trial Radar · NCT02679573

Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial Pneumonia

A Phase 3, Multicenter, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate the Safety and Efficacy of Intravenous to Oral Delafloxacin in Adult Subjects With Community-Acquired Bacterial Pneumonia

Last checked: Nov 20, 2026Latest source record: Feb 27, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 860 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

860

Actual

Start

Dec 14, 2016

Primary completion

Jul 31, 2018

Study completion Aug 7, 2018

Sponsor

Lead sponsor
Melinta Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Feb 10, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of delafloxacin compared to moxifloxacin in the treatment of adult patients with community-acquired pneumonia.

Conditions

  • Community Acquired Bacterial Pneumonia

Interventions

  • DelafloxacinDrug

    Antibacterial agent, 300 mg IV, Q12H for at least 6 doses with potential to switch to 450 mg oral tablet, Q12H for up to 20 doses total

  • MoxifloxacinDrug

    Antibacterial Agent, 400 mg IV, Q24H for at least 3 doses with potential to switch to 400 mg oral over-encapsulated tablet, Q24H for up to 10 doses total

  • LinezolidDrug

    Antibacterial Agent, at local investigator discretion, subjects in the moxifloxacin arm with confirmed MRSA can switch to linezolid 600 mg IV Q12H for all remaining doses

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Early Clinical ResponseTime frame: 96 (+/- 24) hours after the first dose of study drug

Locations

90 sites in 18 countries. Site status is shown where the registry gives one.

  • Melinta 306 Study Site

    Montgomery, Alabama

  • Melinta 306 Study Site

    Newark, Delaware

  • Melinta 306 Study Site

    Coral Gables, Florida

  • Melinta 306 Study Site

    DeBary, Florida

  • Melinta 306 Study Site

    DeLand, Florida

  • Melinta 306 Study Site

    Fort Myers, Florida

  • Melinta 306 Study Site

    Miami, Florida

  • Melinta 306 Study Site

    Miami, Florida

  • Melinta 306 Study Site

    Louisville, Kentucky

  • Melinta 306 Study Site

    Natchitoches, Louisiana

  • Melinta 306 Study Site

    Baltimore, Maryland

  • Melinta 306 Study Site

    Boston, Massachusetts

  • Melinta 306 Study Site

    Burlington, Massachusetts

  • Melinta 306 Study Site

    Saint Paul, Minnesota

  • Melinta 306 Study Site

    St Louis, Missouri

  • Melinta 306 Study Site

    Butte, Montana

  • Melinta 306 Study Site

    Omaha, Nebraska

  • Melinta 306 Study Site

    Newark, New Jersey

  • Melinta 306 Study Site

    Buffalo, New York

  • Melinta 306 Study Site

    Charlotte, North Carolina

  • Melinta 306 Study Site

    Cleveland, Ohio

  • Melinta 306 Study Site

    Dayton, Ohio

  • Melinta 306 Study Site

    Rapid City, South Dakota

  • Melinta 306 Study Site

    Franklin, Tennessee

  • Melinta 306 Study Site

    Corsicana, Texas

  • Melinta 306 Study Site

    Buenos Aires, Argentina

  • Melinta 306 Study Site

    Córdoba, Argentina

  • Melinta 306 Study Site

    La Plata, Argentina

  • Melinta 306 Study Site

    Pleven, Bulgaria

  • Melinta 306 Study Site

    Rousse, Bulgaria

  • Melinta 306 Study Site

    Sofia, Bulgaria

  • Melinta 306 Study Site

    Stara Zagora, Bulgaria

  • Melinta 306 Study Site

    Barranquilla, Colombia

  • Melinta 306 Study Site

    Cali, Colombia

  • Melinta 306 Study Site

    Manizales, Colombia

  • Melinta 306 Study Site

    Medellín, Colombia

  • Melinta 306 Study Site

    Quindío, Colombia

  • Melinta 306 Study Site

    Santo Domingo, Dominican Republic

  • Melinta 306 Study Site

    Tbilisi, Georgia

  • Melinta 306 Study Site

    Leverkusen, Germany

Showing 40 of 90 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.